Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.

Carcinogenesis - 1 May 2005

Simeone Ann-Marie, Deng Chu-Xia, Kelloff Gary J, Steele Vernon E, Johnson Marcella M, Tari Ana M

Abstract excerpt

Women with germline mutations in the breast cancer susceptibility gene BRCA1 are at an increased risk of developing breast cancer. The synthetic retinoid N-(4-hydroxyphenyl)retinamide (4-HPR) has been shown to have a clinical chemopreventive activity in patients with premenopausal breast cancer. Since BRCA1 mutations are associated with an early-onset breast cancer, usually before menopause, we hypothesized that...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Apoptosis
Share to Breast Neoplasms

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to HPR gene

Share to Genes, BRCA1

Share to Mutation

Share to Nitric Oxide

Share to Nitric Oxide Synthase

Share to Tumor Cells, Cultured

Source

Identifiers

PMID: 15695235
DOI: 10.1093/carcin/bgi038

Genes

BRCA1
HPR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

N-(4-Hydroxyphenyl)retinamide is more potent than other phenylretinamides in inhibiting the growth of BRCA1-mutated breast cancer cells.PMID 15695235Read ↗

4-Oxo-Fenretinide, a Recently Identified Fenretinide Metabolite, Induces Marked G2-M Cell Cycle Arrest and Apoptosis in Fenretinide-Sensitive and Fenretinide-Resistant Cell LinesSemantic proximity Read ↗

Synthetic retinoids as inducers of apoptosis in ovarian carcinoma cell lines.Semantic proximity Read ↗

Fenretinide (4-HPR): a preventive chance for women at genetic and familial risk?Semantic proximity Read ↗

Retinoic Acid Receptor β Expression and Growth Inhibition of Gynecologic Cancer Cells by the Synthetic Retinoid N-(4-Hydroxyphenyl) RetinamideSemantic proximity Read ↗

Neuroblastoma cell apoptosis induced by the synthetic retinoid N‐(4‐hydroxyphenyl)retinamideSemantic proximity Read ↗

Chemoprevention of breast cancer.Semantic proximity Read ↗

Fenretinide in Young Women at Genetic or Familial Risk of Breast Cancer: A Placebo-Controlled Biomarker Trial.Semantic proximity Read ↗

Overexpression of the human inducible nitric oxide synthase gene enhances radiation-induced apoptosis in colorectal cancer cells via a caspase-dependent mechanismSemantic proximity Read ↗

EB1089, a synthetic analogue of vitamin D, induces apoptosis in breast cancer cells <i>in vivo</i> and <i>in vitro</i>Semantic proximity Read ↗

Induction of apoptosis by fenretinide (4HPR) in human ovarian carcinoma cells and its association with retinoic acid receptor expressionSemantic proximity Read ↗

Effects of retinoids on cancerous phenotype and apoptosis in organotypic cultures of ovarian carcinoma.Semantic proximity Read ↗

Effect of early vs. late administration of 4-hydroxyphenylretinamide (4-HPR) on N-methyl-N-nitrosourea (MNU)-induced mammary tumorigenesis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.